
Is Abercrombie & Fitch Still A Buy After Its 19% July Surge?
Abercrombie & Fitch (NYSE: ANF) has been thriving—up 19% in July and soaring 6% on July 28 alone. This latest increase was driven by a JPMorgan upgrade to 'Overweight,' with analysts highlighting robust retail momentum in July and a rise in consumer confidence. The firm has elevated its price target to $151, implying additional upside from current prices. This optimism is well-founded. U.S. retail sales improved by 0.6% in May, which is three times more than the anticipated forecast, while jobless claims dropped, indicating strength in the labor market. Adding in Abercrombie's impressive Q1 earnings, it's clear the market has justifiable reasons to trust that the company's transformation narrative is still unfolding.
That being said, for investors seeking lower volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative—it has outperformed the S&P 500 and delivered returns exceeding 91% since its inception.
Fundamentals: Strong Growth, Affordable Stock, Sound Foundation
Abercrombie is not only benefiting from positive macro trends—but it's also performing well. In Q1, the company reported net sales of $1.1 billion (+8%), surpassing expectations, with EPS of $1.59 compared to a consensus of $1.36. It has raised its full-year sales growth guidance to 3–6%, although it slightly reduced EPS forecasts due to tariff issues. Despite its impressive performance, the stock appears undervalued, trading at a P/S of 1.0, P/E of 9.7, and P/FCF of 11.7—all significantly below S&P 500 averages. Revenues have increased at a 10.6% CAGR over the previous three years and have risen 12.5% year-over-year in the past 12 months, significantly outperforming the wider market. No longer merely a legacy mall brand, Abercrombie has redefined itself for the digital age and is connecting with Gen Z shoppers.
The company's balance sheet brings an additional level of assurance, exhibiting a debt-to-equity ratio of 21.1% (better than the S&P average) and a cash-to-assets ratio of 19.6%—almost three times that of the index. Abercrombie is well-financed and poised to reinvest or withstand market turbulence.
Weakness: Margins & Risk of Downturn
Even with strong growth, ANF's profitability lags behind the broader market, with an operating margin of 14.2% in the last four quarters compared to 18.3% for the S&P 500, a net margin of 10.6% against 11.9%, and an operating cash flow margin of 12.2% relative to 19.8%. The stock has also exhibited vulnerability during market downturns, plummeting 70% during the 2022 inflation crisis and 83% in the 2008 financial meltdown. Although it ultimately rebounded in both instances, the historical volatility remains a significant risk for investors.
A Smarter Approach to Navigate the Market
Abercrombie & Fitch presents a rare opportunity in today's market: strong revenue growth, attractive valuation multiples, and a robust balance sheet. While its margins may not match the broader market and the stock has historically struggled during downturns, ANF appears to be an undervalued growth opportunity—especially if consumer spending remains steady and inflation continues to decrease. However, investing in a single stock involves inherent risks, and a diversified strategy may provide greater stability. You might consider exploring the Trefis Reinforced Value (RV) Portfolio, which has outperformed its all-cap stock benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to deliver strong returns for investors. What's the reason? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks provided an agile strategy to optimize returns during favorable market conditions while curbing losses during downturns, as outlined in RV Portfolio performance metrics.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
3 minutes ago
- Bloomberg
Attestor Alumnus Pietro Stella Opens Fund to Raise €250 Million
Fedaia Partners, a London-based alternative investment firm founded by former Attestor partner Pietro Stella in 2020, is seeking to raise €250 million ($289 million) in its first external fundraising. Fedaia is looking for external capital for its strategy focused on below-par investments in European asset-based special situations, according to a person familiar with the matter. The first closing is expected at the end of September, the person added, asking not to be identified discussing a private matter.
Yahoo
30 minutes ago
- Yahoo
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Debenhams to fast-track AI capability across business with new programme
This initiative from Debenhams, developed in partnership with workforce development platform Multiverse, aims to bridge the AI skills gap within its workforce The AI Skills Academy is fully funded through Debenhams Group's £1.35m ($1.79m) Apprenticeship Levy, a UK government-backed fund designed to support work-based learning initiatives. The programme is structured to offer on-the-job learning that contributes directly to the company's operations, said Debenhams. Employees participating in the academy will learn to use AI tools to enhance productivity and engage in more strategic work. Debenhams staff will also be trained to apply AI solutions for streamlining operations and reducing manual tasks. They will also learn building in-house AI systems to expedite the digital transition and decrease dependence on external providers. The new initiative aligns with Debenhams Group's digital transformation roadmap, which emphasises 'innovation and continuous learning'. The programme will be introduced to staff through a comprehensive internal communication campaign, featuring in-person sessions led by Multiverse professionals, said the company. Debenhams Group CEO Dan Finley said: 'Adopting AI is not just about investing in our systems – it's about investing in our people. With the launch of the AI Skills Academy, we're giving our teams the tools to think differently, work smarter and build for the future. This is about unlocking the potential of every colleague to drive real innovation across the Group.' The group offers fashion, home, and beauty products through its various retail brands, including Debenhams, Karen Millen, boohoo, boohooMAN, and PrettyLittleThing. Last month, the company entered into a multi-year partnership with Amazon Web Services (AWS) to leverage AI-driven tools for optimising operations and facilitating the scaling of new brands. A recent research from Pusan National University highlighted the potential for generative AI models like ChatGPT and DALL-E 3 to revolutionise fashion design processes and trend identification within the industry. In June, Debenhams Group engaged Peak to overhaul its pricing and promotions approach, implementing an AI-powered system for setting prices on a vast array of products spanning numerous brands. "Debenhams to fast-track AI capability across business with new programme" was originally created and published by Just Style, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data